Researchers at National Jewish Health and collaborating institutions have uncovered a critical mechanism driving persistent ...
Researchers at Umeå University have contributed new insights into how cancer cells protect themselves from cell death.
Two abstracts reviewed venetoclax, the first FDA-approved BCL-2 inhibitor in acute myeloid leukemia (AML) and a novel BCL-2 inhibitor to treat chronic lymphocytic leukemia/small lymphocytic lymphoma ...
Use of tumor-mediated TRAIL-receptor expression to evaluate apoptotic depletion of infiltrating CD8+ immune cells in clinical colorectal cancer. SPARC microenvironment signature (SMS) in patients ...
Jennifer Brown, MD, PhD, Dana-Farber Cancer Institute, shared her thoughts on the current research regarding Bruton tyrosine kinase (BTK) and B-cell lymphoma 2 (BCL-2) inhibitors in chronic ...
Multimodal treatment of nodal localizations from Merkel cell carcinoma with no identifiable primary site and distant metastases. Background: Mebendazole (MBZ), a microtubule binding agent, is a potent ...
The growth of the BCL-2 inhibitors market is expected to be driven primarily by rising incidence, increased awareness and access to treatment, and the launch of emerging drugs such as Lisaftoclax ...
BUFFALO, NY- September 1, 2022 – A new research paper was published in Aging ("Aging (Albany NY)" by Medline/PubMed, "Aging-US" by Web of Science) on the cover of Volume 14, Issue 16, entitled, ...
China’s National Medical Products Administration approved Ascentage Pharma Group Corp. Ltd.’s Bcl-2 selective inhibitor lisaftoclax (APG-2575) for treating adults with chronic lymphocytic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results